CellaVision
CellaVision is a global medical technology company specializing in the development and sale of advanced solutions for the routine analysis of blood and other body fluids. These solutions are crucial for accurate and swift disease diagnosis, particularly for infections and serious cancer diseases. The company's products, which include automated microscopy systems, replace manual laboratory work, enhancing workflow efficiency and skill development in healthcare facilities. Headquartered in Lund, Sweden, CellaVision operates through global partners and local support organizations in over 40 countries.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIncludes systems for analyzing blood and body fluids.
Consumables used in hematology diagnostics.
Digital tools and applications for laboratory workflows.
Customers
CellaVision primarily serves large laboratories and integrated health networks, which require efficient and accurate diagnostic solutions. The company's products are also used by smaller hospitals that are adopting automation to improve their diagnostic capabilities. Customers value CellaVision's technology for its ability to enhance workflow efficiency and diagnostic certainty. The company's global reach allows it to serve a diverse range of healthcare providers across different regions.
Purchase automated systems for efficient diagnostics.
Use solutions for accurate disease diagnosis.
Adopt automation to enhance diagnostic capabilities.
Strategy
CellaVision's strategic priorities focus on digitalizing microscopy workflows to enhance diagnostic certainty. The company aims to maximize its position in large laboratories and accelerate the adoption of its DC-1 system globally. Expanding leadership in reagents and exploring new analytics areas are also key priorities. These strategies are supported by a strong organizational culture and processes, aiming to establish a global standard for digital microscopy.
To strengthen market leadership
To expand market reach
To enhance product portfolio
Geography
Q4/2025CellaVision operates globally, with significant market presence in the Americas, EMEA, and APAC regions. The company's headquarters are in Lund, Sweden, and it supports its global operations through 12 local market support organizations. The Americas represent a substantial portion of sales, driven by demand from large health networks. EMEA also contributes significantly, particularly in reagent sales, while APAC is a growing market for the company's innovative solutions.
Share of the revenue the company reports by geography.
Risks
CellaVision faces several risks, including reduced demand, currency fluctuations, and production disruptions. The company's reliance on global partners for sales exposes it to geopolitical risks, particularly in volatile regions. The medical technology industry also faces regulatory risks, as compliance with evolving standards is crucial. Additionally, technological advancements by competitors pose a risk to maintaining market leadership.
- Currency fluctuationsImpact: HighLikelihood: Low
Impact on profitability due to exchange rate changes
- Production disruptionsImpact: MediumLikelihood: Low
Potential supply chain issues affecting product availability
Accounting
Judgemental itemsCritical due to global operations
Impact: Significant on earnings
Affect reported earnings
Impact: Material on financial results
Similar listed companies
Publicly listed companies with a comparable business focus.
Vitrolife
VITR · Health Care
Vitrolife Group is a global provider of medical devices and genetic testing solutions focused on reproductive health.
Carasent
CARA · Health Care
Carasent is a Swedish company specializing in digital services for the healthcare industry.
Celularity Inc
CELU · Pharmaceutical Preparations
Celcuity Inc.
CELC · Services-Medical Laboratories
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Revvity, Inc
RVTY · Laboratory Analytical Instruments
Revvity is a U.S.-based health science company that develops instruments, software, reagents, and services used across research, screening, diagnostics, and reproductive health workflows.
Last updated: 24/09/2026